Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes
SGLT2 inhibitors adjunct to insulin improve glycemic control, reduce hyperfiltration, and are generally safe in youth with type 1 diabetes under careful ketone monitoring and DKA risk mitigation.
